Clinical trials: Oral Cancers
Head and Neck Cancer
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy
The purpose of this study is to evaluate the efficacy, safety and tolerability of palifermin on the incidence of oral mucositis in subjects with locally advanced head and neck cancer receiving postoperative radiotherapy.
- Trial name
- NCT00540332
- Testing
- palifermin
- Sponsor
- Swedish Orphan Biovitrum
B-Cell Malignancies
Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
This is a first-in-human (FIH), multicenter, open-label Phase I dose escalation study to evaluate the safety and preliminary efficacy of the TT-01488 tablet, a non-covalent reversible BTK inhibitor, for the treatment of adult…
- Trial name
- NCT05275504
- Testing
- TT-01488
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Prostate Cancer
Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer
The goal of this clinical study is to determine the safety and efficacy of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with…
- Trial name
- NCT02130700
- Testing
- VT-464: given orally twice daily in 28-day cycles, VT-464: given orally once daily in 28-day cycles
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Innocrin Pharmaceutical
Advanced Solid Malignancies
A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies
This study is being carried out to see how single and multiple doses of cediranib are handled by the body (that is how they are absorbed, broken down and got rid of from the body) by measuring levels of drug in the blood in…
- Trial name
- NCT00981721
- Testing
- cediranib (RECENTIN TM, AZD2171)
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Head and Neck Cancer
Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003328
- Testing
- porfiromycin, radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor, Stage IV Gastric Cancer
A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer
A study of DHP107, a novel oral paclitaxel formulation, to determine maximum tolerated dose and recommended dose for phase II trial in patients with advanced solid cancer and explore efficacy of DHP107 in patients with gastric…
- Trial name
- NCT02890511
- Testing
- Paclitaxel
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Daehwa Pharmaceutical Co., Ltd.
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
This study will assess the pharmacokinetics of nilotinib in Ph+ CML pediatric patients that are newly diagnosed or resistant or intolerant to imatinib or dasatinib or refractory or relapsed Ph+ ALL compared to the adult…
- Trial name
- NCT01077544
- Testing
- Nilotinib
- Where
- 12 sites in France, Italy and 2 more
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer
This is a 2-part study in patients with epidermal growth factor receptor mutation positive (EGFRm+) non-small cell lung cancer (NSCLC) whose disease has progressed on treatment with an epidermal growth factor receptor…
- Trial name
- NCT02163733
- Testing
- AZD9291 tablets, Pharmacokinetic sampling - AZD9291, Dietary Fasted
- Where
- 13 sites in France, South Korea and 2 more
- Volunteers
- 38 people
- Sponsor
- AstraZeneca
Cancer
Study to Assess the Safety and Tolerability of MBF-118 in Healthy Volunteers
This is a single center, randomised, double blind, placebo controlled clinical study to assess the safety and tolerability of MBF-118 in healthy volunteers.This clinical phase I trial is divided in two stages and involves, first…
- Trial name
- NCT05921916
- Testing
- MBF-118 oral capsules
- Where
- Spain
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Medibiofarma S.L.
Thrombocytopaenia
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
The study will evaluate the safety and tolerability, optimal biologic dose, and pharmacokinetics of eltrombopag for patients with advanced sarcoma who have a low platelet count and are receiving ADRIAMYCIN and ifosfamide (AI)…
- Trial name
- NCT00358540
- Testing
- eltrombopag
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- GlaxoSmithKline
Recurrent Glioblastoma Multiforme
Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma
This single-center, open-label, phase 2 study will evaluate the anti-tumor activity, as well as the safety and pharmacokinetics, of Panzem (2-methoxyestradiol, 2ME2) Nanocrystal Colloidal Dispersion (NCD) administered in patients…
- Trial name
- NCT00306618
- Testing
- Panzem Nanocrystal Colloidal Dispersion
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- CASI pharmaceuticals, Inc.
Relapsed/Refractory Non-Hodgkin's Lymphoma
A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
A pharmacokinetic study to access how the body absorbs and removes ABT-199 in adults with Non-Hodgkin's Lymphoma.
- Trial name
- NCT02095574
- Testing
- [14C]ABT-199 (GDC-0199)
- Sponsor
- AbbVie
Solid Tumor, Adult, Lymphoma
A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, PK, pharmacodynamics, PGx, and efficacy of fadraciclib administered orally BID.
- Trial name
- NCT04983810
- Testing
- Fadraciclib
- Where
- 4 sites in United States, South Korea and 1 more
- Volunteers
- 330 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Malignancy, Non-hodgkin Lymphoma
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with…
- Conditions
- Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer
- Trial name
- NCT03997968
- Testing
- CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine
- Where
- 16 sites in United States
- Volunteers
- 169 people
- Sponsor
- Cyteir Therapeutics, Inc.
Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy.
- Trial name
- NCT05283226
- Testing
- NRC-2694-A, Paclitaxel
- Where
- 13 sites in United States, India
- Volunteers
- 21 people
- Sponsor
- NATCO Pharma Ltd.
Breast Cancer
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
CONTESSA TRIO is a multi-cohort, multicenter, Phase 2 study of tesetaxel, an investigational, orally administered taxane, in patients with metastatic breast cancer (MBC).
- Trial name
- CONTESSA TRIO (NCT03952325)
- Testing
- Tesetaxel, Nivolumab, Pembrolizumab
- Where
- 12 sites in United States, Singapore and 1 more
- Volunteers
- 294 people
- Sponsor
- Odonate Therapeutics, Inc.
Colorectal Cancer
Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer
This is a randomized, multicenter study designed to evaluate the progression free survival of the SOL group (S-1, Leucovorin, and Oxaliplatin) compared with the mFOLFOX6 group (5-FU, l-LV and Oxaliplatin) as first-line treatment…
- Trial name
- NCT00721916
- Testing
- SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin), mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)
- Where
- Japan
- Volunteers
- 107 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Neoplasms
Relative Bioavailability of Pimasertib in Cancer Patients
This is a Phase 1, multi-center, open-label, single-dose, 2 period, 2 sequence cross-over trial to investigate the relative bioavailability of 2 solid oral pimasertib formulations in cancer subjects (Part A), followed by…
- Trial name
- NCT01992874
- Testing
- Pimasertib Capsule (Part A), Pimasertib Tablet (Part A), Pimasertib Capsule (Part B and trial extension phase)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- EMD Serono
Non-Small Cell Lung Cancer, Metastatic Melanoma
A Study to Investigate 14C-bemcentinib in Healthy Male Subjects
The aims of this Study were to determine: How much of the Study Drug (bemcentinib) ends up in urine and faeces How much of the Study Drug and its breakdown products get into the bloodstream The breakdown products (metabolites) of…
- Conditions
- Non-Small Cell Lung Cancer, Metastatic Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- 8479217 (NCT06469138)
- Testing
- Bemcentinib
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- BerGenBio ASA
Non Small Cell Lung Cancer
A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC
This is an open-label, fixed-sequence Phase I clinical study that evaluates the effect of multiple doses of aumolertinib on the pharmacokinetics of midazolam (CYP 3A4 probe substrate) in sensitive EGFR (Epidermal Growth Factor…
- Trial name
- NCT06926413
- Testing
- Aumolertinib；midazolam
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.